Effectiveness of trimebutine maleate on modulating intestinal hypercontractility in a mouse model of postinfectious irritable bowel syndrome.
Trimebutine maleate, which modulates the calcium and potassium channels, relieves abdominal pain in patients with irritable bowel syndrome. However, its effect on postinfectious irritable bowel syndrome is not clarified. The aim of this study was to investigate the effectiveness of trimebutine maleate on modulating colonic hypercontractility in a mouse model of postinfectious irritable bowel syndrome. Mice infected up to 8 weeks with T. spiralis underwent abdominal withdrawal reflex to colorectal distention to evaluate the visceral sensitivity at different time points. Tissues were examined for histopathology scores. Colonic longitudinal muscle strips were prepared in the organ bath under basal condition or to be stimulated by acetylcholine and potassium chloride, and consecutive concentrations of trimebutine maleate were added to the bath to record the strip responses. Significant inflammation was observed in the intestines of the mice infected 2 weeks, and it resolved in 8 weeks after infection. Visceral hyperalgesia and colonic muscle hypercontractility emerged after infection, and trimebutine maleate could effectively reduce the colonic hyperreactivity. Hypercontractility of the colonic muscle stimulated by acetylcholine and high K(+) could be inhibited by trimebutine maleate in solution with Ca(2+), but not in Ca(2+) free solution. Compared with 8-week postinfectious irritable bowel syndrome group, 2-week acute infected strips were much more sensitive to the stimulators and the drug trimebutine maleate. Trimebutine maleate was effective in reducing the colonic muscle hypercontractility of postinfectious irritable bowel syndrome mice. The findings may provide evidence for trimebutine maleate to treat postinfectious irritable bowel syndrome patients effectively.
Long
Yanqin
Y
Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277, Jiefang Road, Wuhan 430022, China.
Liu
Ying
Y
Tong
Jingjing
J
Qian
Wei
W
Hou
Xiaohua
X
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003106:Colon / Q000187:drug effects / Q000503:physiopathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007422:Intestines / Q000187:drug effects* / Q000503:physiopathology*; D043183:Irritable Bowel Syndrome / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects*; D011188:Potassium / Q000494:pharmacology; D012007:Rectum / Q000187:drug effects / Q000503:physiopathology; D012996:Solutions; D017160:Trichinella spiralis / Q000502:physiology; D014235:Trichinellosis / Q000150:complications*; D014287:Trimebutine / Q000494:pharmacology* / Q000627:therapeutic use
D012996:Solutions; D000109:Acetylcholine; D014287:Trimebutine; D011188:Potassium